New vitamin D receptor ligands

Expert Opinion on Therapeutic Patents

Volumn 13, Issue 6, 2003, Pages 761-772

  Carlberg, Carsten ^a   Mouriño, Antonio ^b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Agonists; Antagonists; GEMINI; Non steroidal analogues; Nuclear receptor; Vitamin D; Vitamin D receptor

Indexed keywords

1,3,24 TRIHYDROXY 26,27 CYCLO 9,10 SECOCHOLESTA 5,7,10(19),22 TETRAENE 25 CARBOXYLIC ACID BUTYL ESTER; 20 EPICALCITRIOL; CALCIPOTRIOL; CALCITRIOL; CALCITRIOL DERIVATIVE; LEXACALCITOL; LG 190178; LIGAND; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEOCALCITOL; TAMOXIFEN; TEI 9647; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR; ZK 168281;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HUMAN; LIGAND BINDING; LIVER CANCER; OSTEOPOROSIS; PANCREAS CANCER; PATENT; PSORIASIS; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0037633229     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.13.6.761     Document Type: Review

References (78)

1. CHAWLA A, REPA JJ, EVANS RM, MANGELSDORF DJ: Nuclear receptors and lipid physiology: opening the X-files. Science (2001) 294:1866-1870.
2. 3. Interplay with retinoid and thyroid hormone signalling. Eur. J. Biochem. (1995) 231:517-527.
3. MORAS D, GRONEMEYER H: The nuclear receptor ligand-binding domain: structure and function. Curr. Opin. Cell Biol. (1998) 10:384-391.
4. GLASS CK, ROSENFELD MG: The coregulator exchange in transcriptional functions of nuclear receptors. Genes & Dev. (2000) 14:121-141.
5. MACIAS GONZALEZ M, CARLBERG C: Cross-repression, a functional consequence of the physical interaction of non-liganded nuclear receptors and POU domain transcription factors. J. Biol. Chem. (2002) 277:18501-18509.
6. 3 receptor-corepressor partnership. FASEB J. (2000) 14:1455-1463.
7. HERDICK M, BURY Y, QUACK M et al.: Response element- and coactivator-mediated conformational change of the vitamin D3 receptor permits sensitive interaction with agonists. Mol. Pharmacol. (2000) 57:1206-1217.
8. RACHEZ C, GAMBLE M, CHANG C-PB et al.: The DRIP complex and SRC-1/p160 coactivators share similar nuclear receptor binding determinants but constitutive functionally distinct complexes. Mol. Cell. Biol. (2000) 20:2718-2726.
9. CARLBERG C: Molecular basis of the selective activity of vitamin D analogues. J. Cell. Biochem. (2003) 88:274-281.
10. 3 and its analogs on growth control and tumorigenesis. Front. Biosci. (2001) 6:D820-D848.
11. BROWN AJ: Therapeutic uses of vitamin D analogues. Am. J. Kidney Dis. (2001) 38:S3-S19.
12. CARLBERG C, BENDIK I, WYSS A et al.: Two nuclear signalling pathways for vitamin D. Nature (1993) 361:657-660.
13. 3receptor (VDR) homodimers into VDR-retinoid X receptor heterodimers. Mol. Cell. Biol. (1994) 14:3329-3338.
14. 3R receptor heterodimer polarity directs ligand sensitivity of transactivation. Nature (1994) 370:382-386.
15. SCHRÄDER M, MÜLLER KM, CARLBERG C: Specificity and flexibility of vitamin D signaling. Modulation of the activation of natural vitamin D response elements by thyroid hormone. J. Biol. Chem. (1994) 269:5501-5504.
16. SCHRÄDER M, BENDIK I, BECKERANDRE M, CARLBERG C: Interaction between retinoic acid and vitamin D signaling pathways. J. Biol. Chem. (1993) 268:17830-17836.
17. 3: past, present, and future. J. Bone Mineral Res. (1998) 13:1360-1369.
18. 3. Mol. Cell. Endocrinol. (2002) 197:1-13.
19. PRÜFER K, RACZ A, LIN GC, BARSONY J: Dimerization with retinoid X receptors promotes nuclear localization and subnuclear targeting of vitamin D receptors. J. Biol. Chem. (2000) 275:41114-41125.
20. SIMONCINI T, HAFEZI-MOGHADAM A, BRAZIL DP et al.: Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature (2000) 407:538-541.
21. 3: separation of genomic and non-genomic vitamin D activities. Bioorg. Med. Chem. (1998) 6:2051-2059.
22. FREEDMAN LP: Multimeric coactivator complexes for steroid/nuclear receptors. Trends Endocrinol. Metab. (1999) 10:403-407.
23. BOUILLON R, OKAMURA WH, NORMAN AW: Structure-function relationships in the vitamin D endocrine system. Endocr. Rev. (1995) 16:200-257.
24. 3 receptor agonists designed for topical treatment of skin diseases. J. Invest. Dermatol. (2001) 116:785-792.
25. JOHNSON CS, HERSHBERGER PA, BERNARDI RJ, MCGUIRE TF, TRUMP DL: Vitamin D receptor: a potential target for intervention. Urology (2002) 60:123-130.
26. EISMAN JA: Genetics of osteoporosis. Endocr. Rev. (1999) 20:788-804.
27. 3 analogs as immunomodulatory agents. Trends Mol. Med. (2002) 8:174-179.
28. COLSTON KW, MACKAY AG, JAMES SY et al.: EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem. Pharmacol. (1992) 44:2273-2280.
29. EVANS TR, COLSTON KW, LOFTS FJ et al.: A Phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br. J. Cancer (2002) 86:680-685.
30. QUACK M, CARLBERG C: Selective recognition of vitamin D receptor conformations mediates promoter selectivity of vitamin D analogs. Mol. Pharmacol. (1999) 55:1077-1087.
31. 3-type vitamin D response elements show a similar functionality in vitro. Biochem. J. (2000) 352:301-309.
32. JONES G, STRUGNELL SA, DELUCA HF: Current understanding of the molecular actions of vitamin D. Physiol. Rev. (1998) 78:1193-231.
33. WU S, REN S, CHEN H et al.: Intracellular vitamin D binding proteins: novel facilitators of vitamin D-directed transactivation [In Process Citation). Mol. Endocrinol. (2000) 14:1387-1397.
34. 3 analogues is not mediated by inhibition of the AP-1 pathway, but may be related to promoter selectivity. Oncogene (1995) 11:1853-1858.
35. 3, that modulates cell growth, differentiation, apoptosis, cell cycle, and induction of PTEN in leukemic cells. Blood (2001) 97:2427-2433.
36. ROCHEL N,WURTZ JM, MITSCHLER A, KLAHOLZ B, MORAS D: Crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol. Cell (2000) 5:173-179.
37. TOCCHINI-VALENTINI G, ROCHEL N, WURTZ JM, MITSCHLER A, MORAS D: Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands. Proc. Natl. Acad. Sci USA (2001) 98:5491-5496.
38. 3 receptor is functionally linked to the transactivation domain 2 (AF-2). Nucleic Acids Res. (1996) 24:4513-4518.
39. 3 and its A-ring-modified analogs. Mol. Endocrinol. (1998) 12:525-535.
40. 3 analogues. Steroids (2001) 66:213-221.
41. 3 analog KH1060. Proc. Natl. Acad. Sci. USA (1996) 93:10685-10690.
42. CORNELLA I, PEREZ SESTELO J, MOURIÑO A, SARANDESES LA: Synthesis of new 18-substituted analogues of calcitriol using a photochemical remote functionalization. J. Org. Chem. (2002) 67:4707-4714.
43. 3 analogues. Bioorg. Med. Chem. Lett (2002) 12:1629-1632.
44. RODRIGUEZ DS, KANZLER S, REISCHL W et al.: A novel class of aromatic vitamin D analogs. Curr. Pharm. Des. (2000) 6:749-754.
45. 3: remarkably high affinity to vitamin D receptor. Org. Lett. (2000) 2:2619-2622.
46. 3 selectively induces bone formation. Proc. Natl. Acad. Sci. USA (2002) 99:13487-13491.
47. 3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2-methylene analogues. J. Med. Chem. (1998) 41:4662-4674.
48. 3: synthesis, conformational analysis, biological activities, and docking to the modeled rVDR ligand binding domain. J. Med. Chem. (2002) 45:3366-3380.
49. 3. Synthesis and preliminary biological evaluation. J. Med. Chem. (1998) 41:3008-3014.
50. MASUDA S, JONES G: Vitamin D analogs-drug design based on proteins involved in vitamin D signal transduction. Curr. Drug Targets Immune Endocr. Metabol. Disord. (2003) 3:43-46.
51. 3. Chem. Biol. (1999) 6:265-275.
52. SWANN SL, BERGH J, FARACH-CARSON MC, OCASIO CA, KOH JT: Structure-based design of selective agonists for a rickets-associated mutant of the vitamin D receptor. J. Am. Chem. Soc. (2002) 124:13795-13805.
53. SCHAPIRA M, RAAKA BM, SAMUELS HH, ABAGYAN R: Rational discovery of novel nuclear hormone receptor antagonists. Proc. Natl. Acad. Sci. USA (2000) 97:1008-1013.
54. 3 receptor. Mol. Pharmacol. (2000) 58:1067-1074.
55. 3 is mediated by a lack of ligand-induced vitamin D receptor interaction with coactivators. J. Biol. Chem. (2000) 275:16506-16512.
56. 3 analogue toward vitamin D receptor function. J. Biol. Chem. (1999) 274:32376-32381.
57. 3 receptor antagonists. Mol. Pharmacol. (2001) 59:1478-1485.
58. 3 receptor for the partial agonism of carboxylic ester antagonists. J. Mol. Biol. (2002) 315:229-238.
59. 3-26,23S-lactone antagonizes the nuclear vitamin D receptor by mediating a unique noncovalent conformational change. Mol. Endocrinol. (2000) 14:1788-1796.
60. MCDONNELL DP: The molecular pharmacology of SERMs. Trends Endocrinol. Metab. (1999) 10:301-311.
61. 3 show cell-specific actions. Chem. Biol. (2000) 7:885-894.
62. 3 with two side chains: interaction with its nuclear receptor and cellular actions. J. Med. Chem. (2000) 43:2719-2730.
63. 3 analogues with two side chains. J. Cell. Biochem. (2001) 81:179-190.
64. 3 receptor by interaction with co-repressors and co-activators. J. Mol. Biol. (2000) 304:793-801.
65. KABAT MM, RADINOV R: The practical synthesis of vitamin D analogs: a challenge for process research. Curr. Opin. Drug Discov. Devel. (2001) 4:808-833.
66. 3). J. Org. Chem. (2000) 65:6978-6983.
67. 2H]-labeled derivative. Org. Lett. (2001) 3:2205-2207.
68. 3 compounds. Org. Lett. (2001) 3:473-475.
69. 3: synthesis and preliminary biological evaluation. J. Med. Chem. (1999) 42:3425-3435.
70. 3: synthesis and biological evaluation. J. Med. Chem. (2000) 43:3581-3586.
71. 2 (calciferol). J. Org. Chem. (1986) 51:4819-4828.
72. CALVERLEY MJ: Synthesis of MC903, a biologically active vitamin D metabolite analogue. Tetrahedron Lett. (1987) 43:4609-4619.
73. HAMMOND ML, MOURIÑO A, OKAMURA WH: Sigmatropic rearrangement of vinylallenes: a novel route to the 1-hydroxyvitamin D system. J. Am. Chem. Soc. (1978) 100:4907-4908.
74. 3. J. Am. Chem. Soc. (1994) 116:6207-6216.
75. ZHU G-H, OKAMURA WH: Synthesis of vitamin D (calciferol). Chem. Rev. (1995) 95:1877-1952.
76. 3. Tetrahedron (1991) 20/21:3485-3489.
77. 3 analogues: stereoselective preparation of 6β-vitamin D vinylallenes and a concise enynol synthesis for preparing the A-ring. J. Org. Chem. (1989) 54:4072-4083.
78. TROST BM, DUMAS J, VILLA M: New strategies for the synthesis of vitamin D metabolites via Pd-catalyzed reactions. J. Am. Chem. Soc. (1992) 114:9836-9845.